Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children

Details

• Alternative Title:
  Vaccine
• Personal Author:
  Raczniak, Gregory A ; Thomas, Timothy K ; Bulkow, Lisa R ; Negus, Susan E ; Zanis, Carolyn L ; Bruce, Michael G ; Spradling, Philip R ; Teshale, Eyasu H ; McMahon, Brian J
• Description:
  Background
  
  Hepatitis A is mostly a self-limiting disease but causes substantial economic burden Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults The hepatitis A vaccine is highly effective but the duration of protection is unknown
  
  Methods
  
  We examined the proportion of children with protective hepatitis A antibody levels (anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12–24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago We compared a subset of data from persons vaccinated with two-doses (720 ELU) at age 3–6 years with a demographically similar prospective cohort that received a three-dose (360 ELU) schedule and have been followed for 17 years
  
  Results
  
  No significant differences were observed when comparing GMC between the two cohorts at 10 (P = 0467), 12 (P = 0496), and 14 (P = 0175) years post-immunization For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years
  
  Conclusion
  
  The two- and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term
  
  
• Subjects:
  Adolescent Article Child Child, Preschool Cohort Studies Female Follow-Up Studies Hepatitis A Hepatitis A Antibodies Hepatitis A Vaccines Humans Immunization Schedule Male Prospective Studies Time Factors Vaccination Vaccines, Inactivated Young Adult

  More +
• Source:
  Vaccine 31(17):2152-2155
• Pubmed ID:
  23470239
• Pubmed Central ID:
  PMC4648811
• Document Type:
  Journal Article
• Funding:
  CC999999/Intramural CDC HHS/United States ; U01PS001097/PS/NCHHSTP CDC HHS/United States ; U50/CCU022279/PHS HHS/United States
• Place as Subject:
  United States
• Location:
  United States
• Volume:
  31
• Issue:
  17
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:97400df5982a006923395ee5c2646148b5a9cc8ca3869843a664685237a9f864
• Download URL:
  https://stacks.cdc.gov/view/cdc/36501/cdc_36501_DS1.pdf
• File Type:
  [PDF - 108.10 KB ]